479 related articles for article (PubMed ID: 29376433)
1. Process, optimization, and characterization of budesonide-loaded nanostructured lipid carriers for the treatment of inflammatory bowel disease.
Sinhmar GK; Shah NN; Chokshi NV; Khatri HN; Patel MM
Drug Dev Ind Pharm; 2018 Jul; 44(7):1078-1089. PubMed ID: 29376433
[TBL] [Abstract][Full Text] [Related]
2. Surface engineered lipid nanoparticle-mediated site-specific drug delivery system for the treatment of inflammatory bowel disease.
Sinhmar GK; Shah NN; Rawal SU; Chokshi NV; Khatri HN; Patel BM; Patel MM
Artif Cells Nanomed Biotechnol; 2018; 46(sup2):565-578. PubMed ID: 29661024
[TBL] [Abstract][Full Text] [Related]
3. Budesonide-loaded nanostructured lipid carriers reduce inflammation in murine DSS-induced colitis.
Beloqui A; Coco R; Alhouayek M; Solinís MÁ; Rodríguez-Gascón A; Muccioli GG; Préat V
Int J Pharm; 2013 Oct; 454(2):775-83. PubMed ID: 23694806
[TBL] [Abstract][Full Text] [Related]
4. Preparation and Characterization of Minoxidil Loaded Nanostructured Lipid Carriers.
Wang W; Chen L; Huang X; Shao A
AAPS PharmSciTech; 2017 Feb; 18(2):509-516. PubMed ID: 27120090
[TBL] [Abstract][Full Text] [Related]
5. Fabrication, optimization, and
Mathur P; Sharma S; Rawal S; Patel B; Patel MM
J Liposome Res; 2020 Jun; 30(2):182-196. PubMed ID: 31060404
[TBL] [Abstract][Full Text] [Related]
6. QbD-driven development and evaluation of nanostructured lipid carriers (NLCs) of Olmesartan medoxomil employing multivariate statistical techniques.
Beg S; Saini S; Bandopadhyay S; Katare OP; Singh B
Drug Dev Ind Pharm; 2018 Mar; 44(3):407-420. PubMed ID: 29048242
[TBL] [Abstract][Full Text] [Related]
7. Development of Oral Lipid Based Nano-formulation of Dapagliflozin: Optimization, in vitro Characterization and ex vivo Intestinal Permeation Study.
Zafar A
J Oleo Sci; 2020; 69(11):1389-1401. PubMed ID: 33132278
[TBL] [Abstract][Full Text] [Related]
8. Quality by Design (QbD)-enabled development of aceclofenac loaded-nano structured lipid carriers (NLCs): An improved dermatokinetic profile for inflammatory disorder(s).
Garg NK; Sharma G; Singh B; Nirbhavane P; Tyagi RK; Shukla R; Katare OP
Int J Pharm; 2017 Jan; 517(1-2):413-431. PubMed ID: 27956192
[TBL] [Abstract][Full Text] [Related]
9. Development, optimization and evaluation of surfactant-based pulmonary nanolipid carrier system of paclitaxel for the management of drug resistance lung cancer using Box-Behnken design.
Kaur P; Garg T; Rath G; Murthy RS; Goyal AK
Drug Deliv; 2016 Jul; 23(6):1912-25. PubMed ID: 25544602
[TBL] [Abstract][Full Text] [Related]
10. Optimization, stabilization, and characterization of amphotericin B loaded nanostructured lipid carriers for ocular drug delivery.
Lakhani P; Patil A; Wu KW; Sweeney C; Tripathi S; Avula B; Taskar P; Khan S; Majumdar S
Int J Pharm; 2019 Dec; 572():118771. PubMed ID: 31669555
[TBL] [Abstract][Full Text] [Related]
11. Sucrose ester stabilized solid lipid nanoparticles and nanostructured lipid carriers. I. Effect of formulation variables on the physicochemical properties, drug release and stability of clotrimazole-loaded nanoparticles.
Das S; Ng WK; Tan RB
Nanotechnology; 2014 Mar; 25(10):105101. PubMed ID: 24531790
[TBL] [Abstract][Full Text] [Related]
12. Preparation and characterization of dutasteride-loaded nanostructured lipid carriers coated with stearic acid-chitosan oligomer for topical delivery.
Noor NM; Sheikh K; Somavarapu S; Taylor KMG
Eur J Pharm Biopharm; 2017 Aug; 117():372-384. PubMed ID: 28412472
[TBL] [Abstract][Full Text] [Related]
13. Design, characterization and skin permeating potential of Fluocinolone acetonide loaded nanostructured lipid carriers for topical treatment of psoriasis.
Pradhan M; Singh D; Murthy SN; Singh MR
Steroids; 2015 Sep; 101():56-63. PubMed ID: 26049018
[TBL] [Abstract][Full Text] [Related]
14. Vincristine and temozolomide combined chemotherapy for the treatment of glioma: a comparison of solid lipid nanoparticles and nanostructured lipid carriers for dual drugs delivery.
Wu M; Fan Y; Lv S; Xiao B; Ye M; Zhu X
Drug Deliv; 2016 Oct; 23(8):2720-2725. PubMed ID: 26203691
[TBL] [Abstract][Full Text] [Related]
15. Implications of formulation design on lipid-based nanostructured carrier system for drug delivery to brain.
Salunkhe SS; Bhatia NM; Bhatia MS
Drug Deliv; 2016 May; 23(4):1306-16. PubMed ID: 25080227
[TBL] [Abstract][Full Text] [Related]
16. In vitro characterization and growth inhibition effect of nanostructured lipid carriers for controlled delivery of methotrexate.
Abdelbary G; Haider M
Pharm Dev Technol; 2013; 18(5):1159-68. PubMed ID: 21958084
[TBL] [Abstract][Full Text] [Related]
17. Metronidazole-loaded nanostructured lipid carriers to improve skin deposition and retention in the treatment of rosacea.
Shinde UA; Parmar SJ; Easwaran S
Drug Dev Ind Pharm; 2019 Jul; 45(7):1039-1051. PubMed ID: 30727789
[TBL] [Abstract][Full Text] [Related]
18. Development and optimization of transferrin-conjugated nanostructured lipid carriers for brain delivery of paclitaxel using Box-Behnken design.
Emami J; Rezazadeh M; Sadeghi H; Khadivar K
Pharm Dev Technol; 2017 May; 22(3):370-382. PubMed ID: 27689412
[TBL] [Abstract][Full Text] [Related]
19. Are nanostructured lipid carriers (NLCs) better than solid lipid nanoparticles (SLNs): development, characterizations and comparative evaluations of clotrimazole-loaded SLNs and NLCs?
Das S; Ng WK; Tan RB
Eur J Pharm Sci; 2012 Aug; 47(1):139-51. PubMed ID: 22664358
[TBL] [Abstract][Full Text] [Related]
20. Effect of liquid-to-solid lipid ratio on characterizations of flurbiprofen-loaded solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) for transdermal administration.
Song A; Zhang X; Li Y; Mao X; Han F
Drug Dev Ind Pharm; 2016 Aug; 42(8):1308-14. PubMed ID: 26707734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
